ArticleFrontiers in pharmacology2020
Pharmacokinetics and Metabolism of Naringin and Active Metabolite Naringenin in Rats, Dogs, Humans, and the Differences Between Species.
Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 108 citations in OpenAlex.
- Preclinical effects of naringin on bone outcomes in animal models of osteoporosis: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Lipid Metabolism Modulation by a Flavonoid-StandardizedJournal of experimental pharmacology · 2026Trial
- The combined effect of green tea and α-glucosyl hesperidin in preventing obesity: a randomized placebo-controlled clinical trial.Scientific reports · 2021Trial
- Synergistic role of naringin and pectin in microwave-assisted green synthesis of stable silver nanoparticles with potent antibacterial activity.Food chemistry: X · 2026Article
- Artificial intelligence-assisted UV-Vis spectrophotometric method for simultaneous quantification of naringin and naringenin in Thymus canoviridis Jalas.BMC chemistry · 2026Article
- Ameliorative effects of gum Arabic-coated selenium nanoparticles on Cisplatin-induced cerebellar neurotoxicity in rats.Scientific reports · 2026Article
- Therapeutic Effects of the Most Common Polyphenols Found inNutrients · 2026Review
- Citrus flavanones (naringenin, hesperidin, and hesperetin) in oral and gastric carcinogenesis: mechanistic insights into oxidative stress, cell death, epigenetic regulation, non-coding RNAs, and tumor microenvironment remodeling.Frontiers in cell and developmental biology · 2026Review
- A 100 mg/kg Dose of Naringenin as an Anti-Obesity Agent for Eight Weeks Exerts No Apparent Hepatotoxic or Nephrotoxic Effects in Wistar Rats.Foods (Basel, Switzerland) · 2025Article
- Biomimetic nanodelivery system with simultaneous blood-brain barrier-crossing and neuroprotective abilities for anti-parkinsonian therapy.Chinese medicine · 2025Article
- Comparative In Vitro Evaluation of Buccal Films, Microcapsules, and Liposomal Systems for Naringin andPharmaceutics · 2025Article
- Review
- Harnessing flavonoids to control probiotic function:Microbiology spectrum · 2025Article
- Strategy for cysteine-targeting covalent inhibitors screening using in-house database based LC-MS/MS and drug repurposing.Journal of pharmaceutical analysis · 2025Article
- Naringenin Decreases Retroperitoneal Adiposity and Improves Metabolic Parameters in a Rat Model of Western Diet-Induced Obesity.Metabolites · 2025Article
- Naringin vs.Antioxidants (Basel, Switzerland) · 2025Article
- Natural compounds regulating fatty acid oxidation in the treatment of diabetic kidney disease.Frontiers in nutrition · 2025Review
- An Updated Review Summarizing the Anticancer Potential of Naringenin.Endocrine, metabolic & immune disorders drug targets · 2025Review
- Naringenin - a potential nephroprotective agent for diabetic kidney disease: A comprehensive review of scientific evidence.Biomolecules & biomedicine · 2024Review
- Anti-depressant effect of Naringenin-loaded hybridized nanoparticles in diabetic rats via PPARγ/NLRP3 pathway.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPharmacokinetics provides a scientific basis for drug product design, dosage regimen planning, understanding the body's action on the drug, and relating the time course of the drug in the body to its pharmacodynamics and/or toxic effects. Recently, naringin, a natural flavonoid, was approved for clinical trials as a first-class new drug product by the China Food and Drug Administration, owing to its nonclinical efficacy in relieving cough, reducing sputum, and low toxicity. Previous reports focused on the pharmacokinetic studies of naringin or its active metabolite naringenin in rats, which were scattered and insufficient because naringin was coadministered with mixtures such as herbs, fruits, and other traditional medicines. The purpose of this study was to evaluate the pharmacokinetics and metabolism of naringin and naringenin, following oral and intravenous administration of naringin in rats, dogs, and humans, which can be beneficial for new drug development.
methodsSeparate bioanalytical methods were developed and validated to determine the concentrations of naringin and its active metabolite naringenin in biological samples obtained from rats, dogs, and humans. Comprehensive nonclinical and clinical data were used to estimate the pharmacokinetic parameters of naringin and naringenin. Experiments included single-dose studies (oral and intravenous administration), multiple-dose studies, and an assessment of food-effects. Furthermore, the metabolism of naringin and naringenin was studied in rat and human liver and kidney microsomes. All biological samples were analyzed using liquid chromatography-tandem mass spectrometry.
resultsThe pharmacokinetic parameters of naringin and naringenin were calculated and the results show an insignificant influence of high-fat diet and insignificant accumulation of the drugs after multiple dosing. Twelve metabolites were detected in the liver and kidney microsomes of rats and humans; naringin metabolism was a complex process simultaneously catalyzed by multiple human enzymes. All evaluated species demonstrated differences in the pharmacokinetics and metabolism of naringin and naringenin.
conclusionThe results can be used to design a dosage regimen, deepen understanding of mechanisms, and accelerate new drug development. CLINICAL
trial registrationhttp://www.chinadrugtrials.org.cn/eap/main, identifiers CTR20130704 and CTR20190127.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.